ReviewGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2016
Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification.
Review in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04886193 (Docetaxel, Oxaliplatin, Fluorouracil), which is not on this map. Cited by 240 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Docetaxel, Oxaliplatin, Fluorouracil (FLOT Regimen) Combined With Teriprizumab (PD-1) in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis: an Open, One-arm, Exploratory Study
Who cites it
240 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Comprehensive Computed Tomography Evaluation of Gastric Cancer: 2026 Consensus Recommendation From the Korean Society of Abdominal Radiology.Korean journal of radiology · 2026Guideline
- Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).Journal of hematology & oncology · 2026Guideline
- Visceral fat area as a prognostic biomarker in gastric cancer: a systematic review and meta-analysis of survival outcomes.Frontiers in oncology · 2025Pooled it
- Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects.Updates in surgery · 2020Pooled it
- Is there a role for treatment-oriented surgery in stage IV gastric cancer? A systematic review.Updates in surgery · 2019Pooled it
- Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.International journal of cancer · 2025Trial
- The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.Cancer medicine · 2020Trial
- Article
- Multimodal approach enables R0 resection in advanced gastric adenocarcinoma with enteroblastic differentiation complicated by portal vein tumor thrombus.Clinical journal of gastroenterology · 2026Article
- Comparison of minimally invasive surgery and open surgery following chemotherapy for cStage IVb gastric cancer: a multicenter retrospective cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Article
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.Clinical journal of gastroenterology · 2026Article
- Sphingolipid metabolic subtyping defines SPHK1 as an oncogene and characterizes immunosuppressive TME features in gastric cancer.Cancer cell international · 2026Article
- Pathological Complete Response Following mFOLFOX6 Plus Zolbetuximab and Conversion Surgery in Initially Unresectable CLDN18.2-Positive Advanced Gastric Cancer: A Case Report.Journal of gastrointestinal cancer · 2026Article
- Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- Development and validation of a composite C-reactive protein-to-albumin ratio-tumor-node-metastasis index for prognostic stratification in gastric cancer: A multicenter cohort study.The Journal of international medical research · 2026Article
- Conversion surgery after response to zolbetuximab-based chemotherapy in Claudin 18.2-positive gastric cancer: a case report.Journal of surgical case reports · 2026Article
- Surgical Intervention After Zolbetuximab-Based Chemotherapy for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A Case Series.Journal of gastrointestinal cancer · 2026Article
- Long-term survival following chemoradiotherapy for postoperative recurrence of hilar cholangiocarcinoma.Clinical journal of gastroenterology · 2026Article
180 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conversion therapy for gastric cancer (GC) has been the subject of much recent attention. It is defined as a surgical treatment aiming at an R0 resection after chemotherapy for tumors that were originally unresectable or marginally resectable for technical and/or oncological reasons. However, the indications for resection remain to be clarified. In the present review, we focus on the biology and heterogeneous characteristics of stage IV GC and propose new categories of classification. Stage IV GC patients can be divided based on the absence (categories 1 and 2) or presence (categories 3 and 4) of macroscopically detectable peritoneal dissemination, which has a different biological outcome compared to hematological metastasis. Category 1 is defined oncologically as stage IV but the metastasis is technically resectable. Category 2 includes a marginally resectable metastasis or patients for whom the operation would not necessarily be the best choice. Category 3 includes a potentially unresectable metastasis of peritoneal dissemination that is only macroscopically detectable. Category 4 includes noncurable metastasis with peritoneal and other organ metastasis. The indications for conversion therapy might include the patients from category 2, some patients from category 3 and a very small number of patients from category 4. The longer survival can be expected for patients corresponding to categories 1, 2 and, to a lesser extent, 3, while the treatment of other patients focuses on "care." The provision of conversion therapy for stage IV GC patients might be one of the main roles of surgical oncologists in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.